跳至主要内容
临床试验/NCT00204451
NCT00204451已完成4 期

Human Ovarian Follicular Dynamics and Emergency Contraception

University of Saskatchewan2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2005年7月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
40
试验地点
2
主要终点
follicle development

研究概览

简要总结

The researchers hypothesize that emergency contraception (EC) will initiate the changes associated with atresia or ovulatory failure at all stages of follicular development and that the image attributes associated with atresia will be similar regardless of the diameter of the dominant follicle when ovarian suppression is initiated. Second, changes associated with atresia may be observed, but ovulation of the dominant follicle is unimpeded.

详细描述

This study is a single-center, randomized, open-label, double-controlled protocol to study the pattern of ovarian follicular growth and regression in two groups of women. The first group will use Plan B, which is a progesterone only OC containing 0.75 levonorgestrel. The second group of women will use the Yuzpe regimen, which uses 50 mg ethinyl estradiol/0.5 mg levonorgestrel pills at different stages of the menstrual follicular cycle.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Female volunteers of childbearing potential;
  • Are first time users of oral contraception (OC) or have discontinued OC at least 1 month prior to study entry;
  • Age between 18 and 40 years old;
  • Normal body mass index (18-38);
  • Has signed informed consent form; and
  • Is in good health as confirmed by medical history, physical examination.

排除标准

  • A positive pregnancy test will automatically exclude the volunteer from participation in this study.
  • Any contraindication for oral contraception use;
  • Irregular menstrual cycles;
  • Ultrasonographic evidence of ovarian dysfunction, such as polycystic ovary syndrome (PCOS);
  • Pregnancy (suspected or diagnosed) or lactation;
  • History or suspicion of drug or alcohol abuse;
  • Participation in an investigational drug trial within the 30 days prior to selection;
  • Exhibits a disorder that is a contraindication to steroid hormonal therapy, including, for example, the following conditions:
  • history of, or actual, thrombophlebitis or thromboembolic disorders.
  • history of, or actual, cerebrovascular disorders.
  • history of, or actual, myocardial infarction or coronary artery disease.
  • acute liver disease.
  • history of, or actual, benign or malignant liver tumors.
  • history of, or suspected, carcinoma of the breast.
  • known, or suspected, estrogen-dependent neoplasia.
  • undiagnosed abnormal vaginal bleeding.
  • any ocular lesion arising from ophthalmic vascular disease, such as partial or complete loss of vision or defect in visual field.

结局指标

主要结局

follicle development

ovulation status

peripheral blood pressure

次要结局

  • endometrial development

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Roger Pierson

Ph.D., FEAS, FCAHS, MS

University of Saskatchewan

研究点 (2)

Loading locations...

相似试验